Purpose: Lamotrigine (LTG), vigabatrin (VGB) and gabapentin (GBP) are three antiepileptic drugs (AEDs) used in the treatment of children with epilepsy for which longterm retention rates are not currently well known. This study examines the efficacy, long-term survival and adverse event profile of these three agents used as add-on therapy in children with refractory epilepsy over a 10-year period. Methods: Three separate audits were conducted between February 1996 and September 2000. All children studied had epilepsy refractory to other AEDs. Efficacy was confirmed if a patient became seizure free or achieved >50% reduction in seizure frequency for 6 months or more after starting therapy. Adverse events and patient survival for each drug were recorded at the end of the study period. Results: Between September 1990 and February 1996, 132 children received LTG, 80 VGB and 39 GBP. At the 10-year follow-up audit, 33% of the children on LTG had a sustained beneficial effect on their seizure frequency in contrast to 19% for VGB and 15% for GBP. No significant difference in efficacy was found in children with partial seizures. Children with epileptic encephalopathy (EE) including myoclonic-astatic epilepsy and Lennox-Gastaut Syndrome (LGS) achieved a more favorable response to LTG. The main reasons for drug withdrawal were lack of efficacy for VGB, apparent worsening of seizures for GBP and the development of a rash for LTG. Conclusions: Lamotrigine is a useful add-on therapy in treating children with epilepsy. It has a low adverse event profile and a sustained beneficial effect in children with intractable epilepsy.
Introduction
Three anti-epileptic agents, lamotrigine (LTG), vigabatrin (VGB) and gabapentin (GBP) provided new add-on drug treatment options for children with refractory epilepsy during the last decade. While numerous studies have examined the safety and efficacy of these agents, there have been few reporting an observation period longer than 4 years. 1 Our study aimed to report the efficacy and adverse event profile of these three anti-epileptic drugs (AEDs) as add-on therapy since they were first licensed for paediatric use in the Republic of Ireland. Survival data for lamotrigine and vigabatrin over a 10-year period and for gabapentin over a 6-year period was obtained.
Methods
A retrospective chart review audit was performed by convenience sampling on patients attending a Children's Seizure Disorder Clinic with refractory epilepsy who were treated with LTG, VGB or GBP as add-on therapy. The initial audit was conducted between February and October 1996. This was repeated between January and November 1998 and again in September 2000. Patients were classified into partial and generalized seizures. The latter group also consisted of a subgroup of children with epileptic encephalopathy (EE) characterized by multiple seizure types, including drop seizures, clinical evidence suggesting intellectual deterioration due to seizures and slow background with slow spike-wave discharges on EEG. The term myoclonic epilepsy has also been used to define this heterogenous group of patients with polymorphous seizures. Our cases included some children with Lennox-Gastaut Syndrome and myoclonic-astatic epilepsy but many could not be classified into a specific epileptic syndrome. For the purpose of this study, we grouped these patients together and designated them as the epileptic encephalopathy (EE) group. All children had been refractory to other standard AEDs at the time of initiation of add-on therapy. Cases were considered refractory if the patient failed to achieve reduction in seizure frequency in response to two or more first line AEDs as judged by doctor or parents. Approval for this study was obtained from the hospital's Ethics Committee. All patients were assessed with regard to the type and duration of epilepsy, seizure frequency, antiepileptic drug (AED) exposure and history of adverse events.
An AED given as add-on therapy was regarded as efficacious if a child became seizure free or had a greater than 50% reduction in seizure frequency within the initial 6-month period. Children who maintained this efficacious response beyond the initial 6-month period were regarded as having achieved sustained benefit. Seizure frequency and adverse events were reassessed during subsequent audits in 1998 and 2000. Where the add-on therapy had been withdrawn for any reason, the duration of time on that particular therapy was recorded. This data was analyzed statistically and Kaplan-Meier survival curves for the 10-year period were constructed.
Results
A total of 176 cases were analyzed during our study period. There were 79 male and 97 female patients. The age at onset of epilepsy ranged from 1 month to 12 years (mean = 3.3 years). There were 73 children with intractable partial seizures, 42 had generalized seizures including absences and there were 61 in the EE group. AEDs used in this study as add-on therapy included LTG 132 (53%), VGB 80 (32%) and GBP 39 (15%).
Children with refractory epilepsy in our clinic were first prescribed VGB in February 1990, LTG in September 1990 and GBP in April 1994. Patients who achieved either seizure freedom or greater than 50% reduction in seizure frequency 6 months after initiation of an add-on AED are recorded (Table 1) . On follow-up, some patients for whom therapy was initially efficacious remained on treatment in the absence of a clear sustained benefit. 50% red: equal or more than 50% reduction of seizure frequency; Sz free: seizure free over a period of at least 6 months.
These were patients for whom control had always been difficult and whose carers were reluctant to permit further changes in treatment. We have extracted these patients and recorded the number with an apparent sustained beneficial effect from their add-on therapy in a separate column (Table 2) . Kaplan-Meier curves were constructed to illustrate survival rates over the study period (Figs. 1-4) . These curves represent all patients remaining on treatment rather than those remaining on treatment with sustained beneficial effect. The data shows LTG to be the most effective of the three add-on AEDs with patient survival on LTG exceeding that for VGB or GBP. Children who became seizure free remained on the same therapy combination or had some of their AED's reduced or withdrawn depending on their degree of seizure control. No patient was weaned to mono-therapy during the study period. Sustained benefit: equal or more than 50% reduction of seizure frequency or seizure free over a period of at least 6 months or more. We observed a number of adverse effects necessitating withdrawal of the add-on therapy over the study period (Table 3) . LTG was the best tolerated with adverse events occurring in 14.5% of patients when lack of efficacy was excluded. The most common adverse event was the development of a rash prompting an immediate withdrawal of LTG. However, reintroduction of LTG at a lower dose was tolerated in a few cases. Excluding lack of efficacy, 25% of patients on VGB and 62% of those on GBP experienced adverse events. Drug intolerance and behavior change were found most commonly with VGB while an aggravation of seizure frequency occurred in 44% of patients on GBP.
Discussion
This study suggests LTG to be the most effective of the three add-on therapies in refractory childhood epilepsy. Significant benefit from the use of LTG as add-on therapy in childhood epilepsy has been previously documented but observation periods have been shorter. [2] [3] [4] Kluger et al. demonstrated that after a similar initial efficacy patients with refractory epilepsies were less likely to be discontinued from LTG than VGB within 5 years. 5 Our study spanning a 10-year period documents a significant sustained benefit from LTG, which also appears to have the lowest adverse event profile of the three anticonvulsants. This is consistent with previous studies identifying this drug as a safe add-on therapy in refractory childhood epilepsy. 6, 7 LTG as add-on therapy was shown to be particularly efficacious in the EE group of patients with sustained efficacy evident in 32%. This contrasts with VGB, which proved a useful add-on drug in only 6% and to GBP, which did not show sustained efficacy in any of the patients in this group. Prospective studies of LTG therapy in children over shorter periods have shown efficacy in LGS but have failed to demonstrate superior efficacy for one intractable treatment group over another. 4, 7 One retrospective study of LTG as add-on therapy in children with refractory epilepsy reported similar findings to ours with 20% of the Lennox-Gastaut Syndrome group and 29% of the Myoclonic-astatic group becoming seizure free. 2 The three AEDs studied in this audit were comparable in efficacy in partial seizures, with 26% (VGB), 33% (LTG) and 27% (GBP) suggesting a sustained beneficial effect. GBP has been shown to be efficacious in partial seizures in children refractory to other AEDs. 8 The order of AED selection in our study suggests that GBP may be more efficacious than LTG in partial seizures. A striking finding in our study was the large percentage of children (44%) with all seizure types who experienced aggravation of seizures on GBP. In our study, GBP was prescribed mainly for partial seizures and 65% of the patients who experienced seizure aggravation were in this group. While our results might suggest some benefit from VGB in refractory partial seizures, reports of associated visual field defects have had a negative impact on its use in patients with epilepsy. 9, 10 Visual field defects were detected in two of our patients treated with VGB before concerns regarding visual field defects were raised.
This study supports previous observations that LTG has a low adverse event profile with a significant and sustained long-term benefit in children with refractory epilepsy including children with epileptic encephalopathy. 
